#triple-negative breast cancer

Study Points Immune System at Triple-Negative Breast Cancer

The Food and Drug Administration recently approved the checkpoint inhibitor Keytruda (pembrolizumab).

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Overall survival increased by 30% among women with aggressive breast cancer who began statin use post-diagnosis.

This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.

PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.

Study offers assurance that the benefits of the combination can be achieved without diminishing patients’ quality of life.

First-line treatment with immunotherapy and a chemotherapy regimen extended progression-free survival by 35%.

Savage X Fenty, the pop superstar’s brand, is known for its dedication to inclusive representation in popular culture.

Adding Tecentriq to a three-drug chemotherapy regimen increases odds of remission of early-stage triple-negative breast cancer.

The honeybee’s sting contains a compound that kills hard-to-treat breast cancer cells quickly.

The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.

Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Keytruda plus chemotherapy reduced the risk of disease progression or death by 35% compared with chemotherapy alone in certain people.

Anne Boyer, a poet and essayist, writes about her experience with triple-negative breast cancer in “The Undying.”